Selecta Biosciences, Inc. To Accelerate Program For Novel Dual Action Vaccine For Malaria
6/17/2014 10:11:42 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--First paragraph, second sentence of release should read: The grant supports the research by Selecta for a novel dual action, immune-activating Synthetic Vaccine Particle (SVP) for malaria. (instead of The grant supports the research by Selecta for a novel dual action, immune-activating SVP (SVP) nanoparticle vaccine for malaria.)
Help employers find you! Check out all the jobs and post your resume.
comments powered by